

EUROPEAN RESPIRATORY *journal*

FLAGSHIP SCIENTIFIC JOURNAL OF ERS



Rate of respiratory symptoms in naïve patients with Chronic lymphocytic leukemia

Kateryna Gashynova, Ganna Usenko

European Respiratory Journal 2020 56: 1913; DOI: 10.1183/13993003.congress-2020.1913

Article

Figures & Data

Info & Metrics

Abstract

Objective: to evaluate the rate of respiratory symptoms (RS) in patients (pts) with Chronic Lymphocytic Leukemia (CLL) and its dependence on anemia, ischemic heart disease (IHD), respiratory diseases, smoking status.

Materials and Methods: Retrospective analysis of medical records of pts' with confirmed CLL who did not receive any treatment. RS (dyspnea, cough, sputum), comorbidity, smoking status were assessed. Parametric and nonparametric statistics were used for the results analysis.

Results: 264 medical records of the pts with CLL who were hospitalized to Dnipro City Hematology Department in 2018 were evaluated. 46 medical records were included on final analysis (35 (76 %) men, age 64.0 (57.0;69.0) years). 8 (17.4%) of pts had dyspnea, 2 (4.3%) – dyspnea and cough, no one had sputum, 36 (78.3%) pts had no RS. According to presence of respiratory symptoms we divided the pts in two groups. Connection of respiratory symptoms with comorbidities and smoking status is present in table. 1

[View inline](#)

There were not any additional investigations of respiratory system performed despite the presence of symptoms.

Conclusions: 21.7 % of naïve pts with CLL had respiratory symptoms which did not associate with comorbid anemia, CLL, respiratory diseases or smoking status. Pts with CLL and RS require more precise examination of respiratory system (spirometry, sputum test and etc.) before the initiation of treatment.

Footnotes

Cite this article as: European Respiratory Journal 2020; 56: Suppl. 64, 1913.

This abstract was presented at the 2020 ERS International Congress, in session “Respiratory viruses in the “pre COVID-19” era”.

This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).

Copyright ©the authors 2020

We recommend

Revefenacin (REV) improves health status and dyspnea regardless of baseline symptom status in chronic obstructive pulmonary disease (COPD): a post hoc analysis of phase 3 trials

Gary T. Ferguson et al., European Respiratory Journal, 2020

Effects of smoking on respiratory problems and functional levels in multiple sclerosis patients

Ridvan Aktan et al., European Respiratory Journal, 2018

Chronic cough in patients presenting to a tertiary cough clinic

Claire Slinger et al., European Respiratory Journal

Socioeconomic impact of chronic cough in Northern Europe

Henrik Johansson et al., European Respiratory Journal, 2020

Diaphragm Efficiency Evaluation in Patients with Connective Tissue Diseases

Enikő Bárczi et al., European Respiratory Journal

Epidemiological and clinical characteristics of coronavirus disease (COVID-19) cases at a screening clinic during the early outbreak period: a single-centre study

Maria Khan et al., J Med Microbiol, 2020

A report of clustered COVID-19 in a hematology ward

Wu et al., Blood Advances

Novel agents in the Canadian therapeutic landscape of chronic lymphocytic leukemia

Anthea C. Peters et al., Oncology Signaling, 2018

MicroRNA as biomarkers and regulators in B-cell chronic lymphocytic leukemia.

Etienne Moussay et al., Proc Natl Acad Sci U S A, 2011

Promises and pitfalls of targeted agents in chronic lymphocytic leukemia

Thomas E. Lew et al., Cancer Drug Resistance-OAE Publishing, 2020

Powered by **TREND MD**

I consent to the use of Google Analytics and related cookies across the TrendMD network (widget, website, blog). [Learn more](#)

Yes

No

[← Previous](#)

[^ Back to top](#)

Vol 56 Issue suppl 64 [Table of Contents](#)

[Table of Contents](#)
[Index by author](#)

-  [Email](#)
-  [Alerts](#)
-  [Citation Tools](#)
-  [Request Permissions](#)
-  [Share](#)

Jump To

- ☒ [Article](#)
- ☐ [Figures & Data](#)
- ☐ [Info & Metrics](#)

Tweet

[Нравится](#) 0

 **More in this TOC Section**

 **Related Articles**

No related articles found.

[Google Scholar](#)

Navigate

- [Home](#)
- [Current issue](#)
- [Archive](#)

About the ERJ

[Journal information](#)

[Editorial board](#)

[Reviewers](#)

[CME](#)

[Press](#)

[Permissions and reprints](#)

[Advertising](#)

The European Respiratory Society

[Society home](#)

[myERS](#)

[Privacy policy](#)

[Accessibility](#)

ERS publications

[European Respiratory Journal](#)

[ERJ Open Research](#)

[European Respiratory Review](#)

[Breathe](#)

[ERS books online](#)

[ERS Bookshop](#)

Help

[Feedback](#)

For authors

[Instructions for authors](#)

[Publication ethics and malpractice](#)

[Submit a manuscript](#)

[ERS author centre](#)

For readers

[Alerts](#)

[Subjects](#)

[Podcasts](#)

[RSS](#)

Subscriptions

[Accessing the ERS publications](#)



Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN: 0903-1936
Online ISSN: 1399-3003

Copyright © 2021 by the European Respiratory Society